Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo (2022)
Attributed to:
RFI Phase 2
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1073/pnas.2203167119
PubMed Identifier: 35881786
Publication URI: http://europepmc.org/abstract/MED/35881786
Type: Journal Article/Review
Parent Publication: Proceedings of the National Academy of Sciences
Issue: 31
ISSN: 0027-8424